Tendon abnormalities, such as increased stiffness, thickness, and excess calcification, occur commonly in patients with diabetes mellitus and cause considerable disability. These changes are frequently attributed to increased cross-linking of extracellular matrix components by advanced glycation end-products (AGEs). However, cellular effects of AGEs, such as increased activity of the cross-linking transglutaminase (Tgase) enzymes, could also contribute to altered tissue biomechanics and calcification in diabetic tendons. We determined the effect of AGE-modified protein on tenocyte Tgase activity.
Research Design and Methods
Primary porcine tenocytes were exposed to Nε- carboxymethyl-lysine (CML)-modified type I collagen in high or normal glucose media. Protein and mRNA levels of the Tgase enzymes and Tgase activity levels were measured, as were markers of apoptosis. We also determined the effect of antioxidants on CML-collagen mediated Tgase activity.
Results
Carboxymethyl-lysine-collagen increased Tgase activity in tenocytes 2.3- to 5.6-fold over unmodified collagen controls in both normal and high glucose media, without altering enzyme protein levels. Anti-oxidant treatment reduced the effect of CML-collagen on Tgase activity. Deoxyribonucleic acid laddering and annexin V protein levels were not altered by CML-collagen exposure.
Conclusions
Carboxymethyl-lysine-collagen increased Tgase activity in tenocytes, likely posttranslationally. Increased levels of Tgase-mediated cross-links may contribute to the excess calcification and biomechanical pathology seen in diabetic tendons.
SukenikS, WeitzmanS, BuskilaD, . Limited joint mobility and other rheumatological manifestations in diabetic patients. Diabete Metab. 1987;13:187–192.
2.
AkturkM, KaraahmetogluS, KacarM, . Thickness of the supraspinatus and biceps tendons in diabetic patients. Diabetes Care. 2002;25:408.
3.
MavrikakisM, DrimisS, KontoyannisD, . Calcific shoulder periarthritis (tendinitis) in adult onset diabetes mellitus: a controlled study. Ann Rheum Dis. 1989;48:211–214.
4.
GrantW, SullivanR, SonenshineD, . Electron microscopic investigation of the effects of diabetes mellitus on the Achilles tendon. J Foot Ankle Surg. 1997;36:272–278.
5.
JimY, HsuH, ChangC, . Coexistance of calcific tendonitis and rotator cuff tear: an arthrographic study. Skeletal Radiol. 1993;22:183–185.
6.
Moren-HybbinetteI, MoritzU, ScherstenB.The clinical picture of the painful diabetic shoulder- natural history, social consequences and analysis of the concomitant hand syndrome. Acta Med Scand. 1987;221:73–82.
7.
VogtB, SchleicherE, WielandO. ɛ-amino-lysine-bound glucose in human tissues obtained at autopsy: Increase in diabetes mellitus. Diabetes. 1982;31:1123–1127.
8.
LancasterR, HautR, DeCampC.Changes in the mechanical properties of patellar tendon preparations of spontaneously diabetic dogs under long term insulin therapy. J Biomech. 1994;27:1105–1108.
9.
NahS-S, ChoiI-Y, YooB, . Advanced glycation end products increases matrix metalloproteinase-1 -3, and -13, and TNF-alpha in human osteoarthritic chondrocytes. FEBS Lett. 2007;581:1928–1932.
10.
KislingerT, FuC, HuberB, . N(epsilon)-carboxymethyl)lysine adducts of proteins are ligands for receptors for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem. 1999;274:31740–31749.
11.
AlikhaniM, AlikhaniZ, BoydC, . Advanced glycation end products stimulate osteoblast apoptosis via the MAP kinase and cystolic apoptotic pathways. Bone. 2007;40:345–353.
12.
AlikhaniZ, AlikhaniM, BoydC, . Advanced glycation end products enhance expression of pro-apoptotic genes and stimulate fibroblast apoptosis through cytoplasmic and mitochondrial pathways. J Biol Chem. 2005;280:12087–12095.
13.
LorandL, GrahamR.Transglutaminases: crosslinking enzymes with pleiotrophic functions. Nature. 2003;4:140–157.
14.
DouthwaiteJ, JohnsonT, HaylorJ, . Effects of transforming growth factor-beta1 on renal extracellular matrix components and their regulating factors. J Am Soc Nephrol. 1999;10:2109–2119.
15.
AeschlimannD, MosherD, PaulssonM.Tissue transglutaminase and Factor XIII in cartilage and bone remodeling. Semin Thromb Hemost. 1996;22(5):437–443.
16.
HeinkelD, GohrC, UzukiM, . Transglutaminase contributes to CPPD crystal formation in osteoarthritis. Front Biosci. 2004;9:3257–3261.
17.
El NahasA, Abo-ZenahH, SkillN, . Elevated e- (γ- Glutamyl)lysine in human diabetic nephropathy results from increased expression and cellular release of tissue transglutaminase. Nephron Clin Pract. 2004;97:c108–17.
18.
SkillN, JohnsonT, CouttsI, . Inhibition of transglutaminase activity reduces extracellular matrix accumulation induced by high glucose levels in proximal tubular epithelial cells. J Biol Chem. 2004;279:47754–47762.
19.
NagyL, ThomazyV, SaydakM, . The promoter of the mouse tissue transglutaminase gene directs tissue-specific, retinoid-regulated and apoptosis-linked expression. Cell Death Differ. 1997;4:534–547.
20.
LanbertiP, WezemanF.Biologic behavior of an InVitro hydrated collagen-human tenocyte tendon model. Clin Orthop Rel Res. 2002;397:414–423.
21.
Schulze-TanzilG, MobasheriA, CleggP, . Cultivation of human tenocytes in high-density culture. Histochem Cell Biol. 2004;122:219–228.
22.
KerteszG, BourcierB, CaillaH, . Immunoradiometric assay of succinylated corticotropin: an improved method for quantification of ACTH. Clin Chem. 1998;44:78–85.
23.
MonnierV, BautistaO, KennyD, . Skin collagen glycation, glyoxidation, and crosslinking are lower in subjects with long-term intensive versus conventional therapy of type I diabetes. Diabetes. 1999;48:870–880.
24.
RosenthalAK, DerfusBA, HenryLA.Transglutaminase activity in aging articular chondrocytes and articular cartilage vesicles. Arthritis Rheum. 1997;40(5):966–970.
25.
LowryO, RosebroughN, FarrA, . Protein measurement with Folin-phenol reagent. J Biol Chem. 1951;193:265–275.
26.
D'ArgenioG, CalvaniM, Della ValleN, . Differential expression of multiple transglutaminases in human colon: impaired keratinocyte transglutaminaes expression in ulcerative colitis. Gut. 2005;54:496–502.
27.
SunY, KandelR.Deep zone articular chondrocytes in vitro express genes that show specific changes with mineralization. J Bone Miner Res. 1999;14:1916–1925.
28.
van de MerbelN, MentinkC, WolfenbuttelB.Liquid chromatographic method for the quantitative determination of N-carboxymethyllysine in human plasma proteins. J Chromatogr. 2004;808:163–168.
29.
SchleicherE, WagnerE, NerlichA.Increased accumulation of the glycoxidation product Ne-(carboxymethyl)lysine in human tissues in diabetes and aging. J Clin Invest. 1997;99:457–468.
30.
NakanoY, Al-jalladH,MousaA, . Expression and localization of plasma transglutaminase factor XIIIA in bone. J Histochem Cytochem. 2007;55:675–685.
31.
RosenthalA, MasudaI, GohrC, . The transglutaminase, Factor XIIIA, is present in articular chondrocytes. Osteoarthritis Cartilage. 2001;9:578–581.
32.
LinC-L, WangF-S, KuoY, . Ras modulation of superoxide activates ERK-dependent fibronectin expression in diabetes-induced renal injuries. Kidney Int. 2006;69:1593–1600.
33.
GroenenP, SecciaM, SmuldersR, . Exposure of βH-crystallin to hydroxyl radicals enhances the transglutaminase susceptibility of its existing amine-donor and amine acceptor sites. Biochem J. 1993;293:399–404.
SkillN, GriffinM, El NahasA, . Increases in renal ɛ -(γ -glutamyl)lysine crosslinks results from compartment-specific changes in tissue transglutaminase in early experimental diabetic nephropathy; Pathologic implications. Lab Invest. 2001;81:705–716.
36.
BernassolaF, FedericiM, CorazzariM, . Role of transglutaminase 2 in glucose tolerance: knockout mice studies and a putative mutation in a MODY patient. FASEB J. 2002;16:1371–1378.
37.
HolmesF, HaynesL.Superactivation of transglutaminase type 2 without change in enzyme level occurs during progressive neurodegeneration in the mnd mouse. Neurosci Lett. 1996;213:185–188.
